SMAIO (ALSMA) Q4 2024 TU earnings summary

Executive summary

• 2024 sales reached €5.5 million, up 110% year-over-year excluding a prior milestone payment.

• Over half of revenue now generated in the United States, reflecting a strategic shift and strong market adoption.

• Relocation of sales and general management to Dallas, Texas, and establishment of a North American Scientific Advisory Board.

Financial highlights

• Implant sales grew 119% to €5.3 million compared to 2023.

• US implant sales surged 779% year-over-year to €2.9 million, now 53% of total sales.

• Group sales excluding exceptional milestone payment increased 110% year-over-year.

• Q4 US sales hit a record €1.5 million.

Outlook and guidance

• Continued US expansion planned for 2025, with direct and partner distribution.

• Registration in 5 new US centers underway, aiming for 13 user centers soon.

• Sustained growth momentum expected, supported by innovation and positive surgeon feedback.